PCN17 THE HEALTH CARE COST OF SMOKING IN CANADA  by Petit, P et al.
251Abstracts
PCN17
THE HEALTH CARE COST OF SMOKING IN CANADA
Petit P1, Cremieux P2, Ouellette P3
1Groupe d’analyse, inc, Montreal, QC, Canada; 2Analysis Group,
Boston, MA, USA; 3Universite’ du Quebec a Montreal, Montreal, QC,
Canada
OBJECTIVES: Adverse health effects resulting from tobacco
smoking are associated with a signiﬁcant economic burden and
could be reduced through smoking-related health risk awareness
programs. The purpose of this paper is to measure health care
costs savings achievable by reducing smoking prevalence, and 
to simulate the costs and beneﬁts of an awareness program.
METHOD: A regression analysis was performed to link the
prevalence of smoking and the number of cigarettes smoked
daily by smokers to the incidence of: 1) lung cancer; 2) cancer
of the mouth; 3) heart disease; 4) cerebro-vascular disease; and
5) chronic obstructive pulmonary disease (COPD) in Canada
based on data from Statistics Canada (smoking prevalence) and
Health Canada (medical conditions). For each condition, the
reduction in the number of cases following a decrease in smoking
prevalence and in the number of cigarettes smoked was esti-
mated, and health care costs savings were calculated with con-
dition-speciﬁc unit cost estimates. The impact of a smoking
reduction program was simulated based on the impact of such
programs in the US, and its costs compared with resulting health
care costs savings. RESULTS: A one percent reduction in
smoking prevalence in Canada is associated with a reduction of
62 cases of cancer of the mouth, 98 lung cancer cases, 2835 heart
disease cases, 592 cerebrovascular disease cases, and 1263
COPD cases. These translate into health care cost savings of
$65.7CAN millions annually. Based on these estimates, a 10-year
smoking reduction program with costs and impact similar to that
implemented in California in the 1990s would have a net beneﬁt
ranging from CAN $1.7 billion to CAN $3.7 billion. CON-
CLUSIONS: Smoking is statistically related to many health con-
ditions and health care costs associated with these conditions can
be reduced through decreased smoking. Tobacco-reduction 
programs would yield substantial net beneﬁts to the Canadian
government.
PCN18
COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN
Yang CH, Chang CJ
National Taiwan University Hospital,Taipei,Taiwan
OBJECTIVE: Lung cancer is the leading cause of cancer death
in Taiwan. According to the statistics published by the Taiwan
Department of Health, 6555 patients died from lung cancer in
2001, and the mortality rate was 29.34 per 100,000 people. The
purpose of this study was to analyze the direct cost of lung cancer
management in Taiwan. METHODS: The claim database of the
Bureau of National Health Insurance in Taiwan was used for this
study, including the hospitalization and outpatient expenses for
2000 and 2001. The analyses comprised the average costs of hos-
pitalization or outpatient services for lung cancer patients.
RESULTS: Of the total hospitalization events for the year 2001,
56.86% were for chemotherapy administration (ICD-9-CM =
V581). The average number of in-hospital days was 4.8, and the
average cost for each event was NTD30, 648 (USD907.55)
(1USD = 33.77NTD). Febrile neutropenia, thrombocytopenia,
nausea and vomiting, neuropathy, and anemia were the common
causes of hospitalization in large-scale global phase III clinical
studies, but in Taiwan, only febrile neutropenia (144 events,
NTD 47,191 [USD 1,397.42]/event), and nausea and vomiting
(19 events, NTD19,361 [USD573.32]/event) were claimed in
2001. In addition, the average cost of outpatient chemotherapy
and non-chemotherapy service was NTD16,977 (USD502.72)
and NTD3,051 (USD90.35), respectively in 2001. CONCLU-
SION: This study adapts the database of the Taiwan Bureau of
National Health Insurance for the years 2000 and 2001 to a
descriptive analysis. The limitations of this research include the
complex nature of the disease, the multiple reasons for admis-
sion, and the imprecision of coding by health care providers.
Note: This study is based in part on data from the National
Health Insurance Research Database provided by the Bureau of
National Health Insurance, Department of Health and managed
by the National Health Research Institutes. The interpretation
and conclusions contained herein do not represent those of the
Bureau of National Health Insurance, Department of Health or
National Health Research Institutes.
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THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT
HUMAN ERYTHROPOIETIN GROWTH FACTORS VS.
TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS
Tonnu IQ, Hay JW
USC School of Pharmacy, Los Angeles, CA, USA
Chemotherapy-induced anemia is currently treated with recom-
binant human erythropoietin growth factors (rHu-EGFs) or
transfusion. Currently, most studies ﬁnd that that blood trans-
fusion is more cost effective compared to rHu-EGFs due to the
high cost and relatively small quality of life (QOL) improvements
from the drugs. OBJECTIVES: To measure the cost effectiveness
of using blood transfusion vs. rHu-EGFs in chemotherapy-
treated cancer patients from the societal perspective and cost per
quality-adjusted life-year (QALY) approach. METHODS: A
spreadsheet model was used to evaluate the cost effectiveness of
erythropoietin (EPO) or darbepoietin (DARB) plus transfusion
when needed, compared to transfusion only. The model applied
clinical and QOL data from previous clinical trials and existing
literature, in an expected present value backwards induction
model using DEALE survival modeling to estimate cost per
QALY. In the base case, patients were 60 years old, weighed 60
kg and used the manufacturer’s recommended doses for
chemotherapy-related anemia. The model’s time horizon was one
year. A sensitivity analysis was performed to determine model
robustness. RESULTS: In the base case and relative to infusion
only, for each patient who received EPO, the cost per QALY was
$25,152, whereas, the cost per QALY was $45,646 for DARB.
The sensitivity analysis suggested that the model was only sen-
sitivity to QOL assumption, when the probability of infusion and
anemia was altered by 25%, the cost per QALY values for EPO
were $24,847–$25,473 and $21,419–$30,039, respectively.
Also, an 81% reduction in DARB dose or price would be needed
to equalize the cost of DARB treatment with that of EPO. CON-
CLUSIONS: This economic model demonstrates that treating
chemotherapy-related anemia using rHu-EGFs is more cost-
effective than transfusion only. Also, current clinical data sug-
gests that there are no signiﬁcant QALY differences between the
rHu-EGFs. Thus, EPO would be the dominant alternative.
PCN20
PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN
CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY
SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS 
OF AGE
Zammit D, Hay J
University of Southern California, Los Angeles, CA, USA
The American Cancer Society Guidelines (ACS) recommends
women at average risk for breast cancer to begin annual 
